COVID-19 has killed scores of individuals globally within the last 4 years. Nevertheless, now a recent research suggests that it holds the potential to revolutionize the way in which cancer is treated.

A team of Australian researchers have closely scrutinized the attributes of the SARS-CoV-2 virus, and concluded that folks’s natural immunity to the pathogen might be the important thing to treating different sorts of cancer.

Researchers on the Peter MacCallum Cancer Center and the University of Melbourne discovered that through the use of chimeric antigen receptor (CAR) therapy on the T cells, which naturally occur in white blood cells and make the body resistant to viruses, a recent treatment of cancer might be introduced.

The T-cell build-up occurs after an individual had COVID or was vaccinated against it. These are then genetically treated to provide the special receptors called CAR, that are empowered to discover any antigen on the surface of cancer cells and effectively eliminate it at an early stage.

During their research, the scientists took some T cell samples from people belonging to the said groups and genetically re-engineered them to discover and goal cancer cells. These cells were then reinjected back to the body, and as T cells can recognize the COVID-19 virus spike protein, they’re then activated by a vaccine, National Breast Cancer Foundation reported.

“This recent research is actually exciting, it uses COVID-19 immunity, T ‘killer’ cells, to acknowledge COVID, engineers them to attack breast cancer cells–really clever,” professor Robert Booy, who was related to the research, told 9 News.

Nevertheless, the therapy has turned out to be successful just for limited varieties of cancers. The research found the method can treat some sorts of blood cancers, but can’t still treat solid tumors. Researchers are hoping they’ll reach that time soon because it has yielded positive leads to test tubes.

Human trials of the therapy are expected to start inside the subsequent three years.

“It’s a unprecedented, almost a once-in-a-lifetime opportunity to make use of what is sort of population-wide immunity to Covid-19 to harness that potential to treat breast cancer,” professor Cleola Andereisz said.